ClinicalTrials.gg
RecruitingNCT06970522Updated Mar 25, 2026

Wearable Sensors to Detect Atypical Muscle Activation in Young Infants

An observational study in Neuromuscular Disorders, Motor Development and Muscle Tone, sponsored by Shirley Ryan AbilityLab. Recruiting at 2 sites in United States. Open to participants aged 0 Months to 8 Weeks. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Shirley Ryan AbilityLab · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
0 Months to 8 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.

Planned enrollment
32nd of 46
40 · median 82
Started
2025
with 9 others
Observational
46 of 120
17 open now
Primary completion
2026-12
later than 8 of 38 live
Registered
105th of 120
by date

Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 32nd largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2025, is one of 46 observational ones, reaches primary completion later than 8 of the 38 other live ones, and was the 105th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 0 Months to 8 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Neuromuscular Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and/or identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.

03

Conditions studied

  • Neuromuscular Disorders
  • Motor Development
  • Muscle Tone

Keywords

  • Early Detection
  • Wearable Sensors
04

Who can participate

Ages eligible
0 Months to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants presenting with atypical muscle tone based on clinical expertise along with infants expected to have typical development.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Infants with low tone:
  • Hospitalized in the NICU
  • AND >38 weeks post-menstrual age
  • AND abnormal normal brain imaging OR Apgar score \<7 at five minutes with umbilical cord pH (if obtained) \<7.15
  • AND 2 or more warning signs for muscle tone or posture using the HNNE short form
  • AND legal guardian able and willing to give written consent and comply with study procedures
  • For Infants with typical tone:
  • Born at 38-41 weeks of gestation
  • AND hospitalized after birth in the NICU OR well newborn nursery
  • AND infants with appropriate for gestational age birth weight
  • AND HNNE exam (short proforma) normal with no warning signs for any parameter
  • AND legal guardian able and willing to give written consent and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Infants of Both Low Tone and Typical Tone Cohorts:
  • Missing or incomplete limbs (such as from amputation or congenital limb defects).
  • Open wounds or skin breakdown on the limbs or torso.
  • Presence of known genetic syndrome or congenital anomalies requiring surgery or affecting function
  • Use of sedative medications (may include phenobarbital if level stable and therapeutic)
  • Legal guardian unable to give written consent and comply with study procedures.
  • Does not receive medical clearance from a physician to participate in the study if the individual is receiving inpatient care.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infants with Typical Tone
  • Infants with Low Tone
06

What researchers measure

Primary outcomes

  1. Correlation Between EMG Data and Observed Muscle Tone Before 8 Weeks Corrected Age

    Correlation of EMG sensor data and Hammersmith Neonatal Neurological Exam (HNNE) short form score, assessed before 8 weeks corrected age.

    Time frame: Before 8 weeks corrected age

Secondary outcomes

  1. Estimation of Clinical Scores Performed Before 8 Weeks Corrected Age Using EMG Data

    Error between true clinical test scores and estimated scores using EMG sensor data, assessed before 8 weeks corrected age.

    Time frame: Before 8 weeks corrected age

07

Study locations

2 of 2 sites recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
    • Raye-Ann Odegaard deRegnier, MD · Principal investigator
  • Shirley Ryan AbilityLab
    Chicago, Illinois 60611, United States
    Recruiting
    • Arun Jayaraman, PT, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06970522
Responsible party
Arun Jayaraman, PT, PhD (Principal Investigator, Shirley Ryan AbilityLab) — Principal investigator
First posted
May 14, 2025
Start date
Jun 25, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 25, 2026

Study contacts

Rachel Andersen
Contact
randersen@sralab.org
312-238-1476
Megan O'Brien, PhD
Contact
mobrien02@sralab.org
312-238-2289
Arun Jayaraman, PT, PhD
principal investigator · Shirley Ryan AbilityLab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion